收藏切换
Progress in the development of therapeutic targets and drugs for non-alcoholic steatohepatitis
收藏切换
Yujie FU1, 2, Xihui CHEN1, 2, Minyu LIU1, 2, *
World Clinical Drug | 2025, 46(2) : 123 - 129
Less
收藏切换
World Clinical Drug | 2025, 46(2): 123-129
• Topic •
Progress in the development of therapeutic targets and drugs for non-alcoholic steatohepatitis
Full
Yujie FU1, 2, Xihui CHEN1, 2, Minyu LIU1, 2, *
Affiliations
  • 1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
Published: 2025-02-10 doi: 10.13683/j.wph.2025.02.002
Outline
收藏切换

Non-alcoholic steatohepatitis(NASH), as a chronic metabolic disease, is closely related to obesity, diabetes mellitus type 2, hyperlipidemia and other metabolic syndromes. Its pathogenesis involves multiple factors such as genetics, environment and lifestyle, especially metabolic disorders as the core driving force, which promote disease progression through oxidative stress, endoplasmic reticulum stress and inflammatory pathway activation. For the treatment of NASH, multiple potential therapeutic targets have been identified, such as metabolic regulation, blocking of inflammatory pathways, and anti-fibrosis. NASH may also progress to severe diseases such as cirrhosis and liver cancer, which poses a major threat to human health. In addition, NASH is often accompanied by other metabolic diseases, forming a vicious cycle that further increases the difficulty of treatment and the burden on patients. This article aims to comprehensively review the pathogenesis, therapeutic targets and drug research progress of NASH, and discuss its harm to humans, so as to provide reference for future research and clinical practice.

non-alcoholic steatohepatitis  /  metabolism  /  therapeutic targets  /  progress in drug development
傅宇洁, 陈曦慧, 刘珉宇. 非酒精性脂肪性肝炎治疗靶点及药物研发进展. 世界临床药物, 2025 , 46 (2) : 123 -129 . DOI: 10.13683/j.wph.2025.02.002
Yujie FU, Xihui CHEN, Minyu LIU. Progress in the development of therapeutic targets and drugs for non-alcoholic steatohepatitis[J]. World Clinical Drug, 2025 , 46 (2) : 123 -129 . DOI: 10.13683/j.wph.2025.02.002
Year 2025 volume 46 Issue 2
50
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.02.002
  • Receive Date:2024-08-27
  • Online Date:2026-11-09
  • Published:2025-02-10
Article Data
Affiliations
History
  • Received:2024-08-27
Affiliations
    1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.02.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT